Monopar Therapeutics Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Note 7 - Net Loss Per Share

Note 7 - Net Loss Per Share

9 Months Ended

Sep. 30, 2025

Notes to Financial Statements

Earnings Per Share [Text Block]

Note 7 – Net Loss Per Share

Basic and diluted net loss per common share was calculated as follows:

	*Three Months Ended September 30,*						*Nine Months Ended September 30,*
(in thousands, except for net loss per share)	*2025*			2024**			*2025*			2024**
Numerator:
Net loss	$	(3,438	)	$	(1,304	)	$	(8,516	)	$	(4,661	)

Denominator:
Weighted-average common shares outstanding, basic and diluted		7,124			3,520			7,037			3,419

Net loss per common share, basic and diluted	$	(0.48	)	$	(0.37	)	$	(1.21	)	$	(1.36	)

Anti-dilutive potential common stock equivalents excluded from the calculation of net loss per share:
Stock options to purchase common stock		601			429			601			429
Unvested restricted stock units		115			48			115			48

^**Information pertaining to the number of shares outstanding gives retroactive effect to a 1 for 5 reverse stock split that became effective on August 12, 2024.